Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Cell Press 2017

Ижил төстэй зүйлс

Myelodysplastic syndromes: moving towards personalized management
-н: Eva Hellström-Lindberg, зэрэг
Хэвлэсэн: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
-н: Jädersten, M, зэрэг
Хэвлэсэн: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
-н: Follo, M, зэрэг
Хэвлэсэн: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
-н: H. Dohner, зэрэг
Хэвлэсэн: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
-н: Garcia-Manero, G, зэрэг
Хэвлэсэн: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2012)

5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
-н: Svensson, T, зэрэг
Хэвлэсэн: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
-н: A. Schuh, зэрэг
Хэвлэсэн: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
-н: Garcia-Manero, G, зэрэг
Хэвлэсэн: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
-н: Garcia-Manero, G, зэрэг
Хэвлэсэн: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
-н: L. Adès, зэрэг
Хэвлэсэн: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
-н: S. de Botton, зэрэг
Хэвлэсэн: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
-н: R Edlin, зэрэг
Хэвлэсэн: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
-н: R Edlin, зэрэг
Хэвлэсэн: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
-н: A. Schnegg-Kaufmann, зэрэг
Хэвлэсэн: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
-н: Garcia-Manero, G, зэрэг
Хэвлэсэн: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
-н: Scharenberg, C, зэрэг
Хэвлэсэн: (2011)

Gene expression profiling in the myelodysplastic syndromes.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
-н: Sara Mongiorgi, зэрэг
Хэвлэсэн: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
-н: Armstrong, R, зэрэг
Хэвлэсэн: (2017)

Advances in the 5q- syndrome.
-н: Boultwood, J, зэрэг
Хэвлэсэн: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
-н: Pellagatti, A, зэрэг
Хэвлэсэн: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
-н: Anjali Bhatt, зэрэг
Хэвлэсэн: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
-н: Chiara R. Dart, зэрэг
Хэвлэсэн: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
-н: Nikpour, M, зэрэг
Хэвлэсэн: (2010)